Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the first anti-CD38 therapy with VRd to significantly reduce disease progression or death by 40%.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with Velcade (bortezomib),
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020,
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
PharmiWeb
1h
Sarclisa approved in the US as the first anti-CD38…
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
12d
Multiple myeloma gets new attention after Patti Scialfa, Bruce Springsteen's wife and bandmate, reveals diagnosis
Patti Scialfa, Bruce Springsteen’s wife and bandmate, said she has multiple myeloma. Here's what to know about the blood ...
9d
on MSN
Multiple myeloma, rare blood cancer: Bruce Springsteen's wife's diagnosis spotlights the illness
Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...
The American Journal of Managed Care
2d
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
Cure Today
3d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with
multiple
myeloma
who ...
10d
Patti Scialfa's Cancer Diagnosis: What To Know About Multiple Myeloma
Patti Scialfa, Bruce Springsteen’s Wife and E Street Bandmate, has been diagnosed with multiple myeloma. Find out more on ...
The American Journal of Managed Care
3d
Varied Types, Levels of Support Needed for Patients With Multiple Myeloma
Information on the disease and treatments, assistance with insurance, and transportation are among the types of support ...
Hosted on MSN
22h
Moving mountains: Boulder woman's battle against multiple myeloma during Blood Cancer Awareness Month
A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Sanofi
Sarclisa
Blenrep
isatuximab
Food and Drug Administration
Feedback